Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 1.62
CRIS's Cash-to-Debt is ranked lower than
78% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. CRIS: 1.62 )
Ranked among companies with meaningful Cash-to-Debt only.
CRIS' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.17  Med: 7.65 Max: No Debt
Current: 1.62
Equity-to-Asset 0.37
CRIS's Equity-to-Asset is ranked lower than
90% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CRIS: 0.37 )
Ranked among companies with meaningful Equity-to-Asset only.
CRIS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.12  Med: 0.7 Max: 0.95
Current: 0.37
0.12
0.95
Debt-to-Equity 1.41
CRIS's Debt-to-Equity is ranked lower than
98% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. CRIS: 1.41 )
Ranked among companies with meaningful Debt-to-Equity only.
CRIS' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.22 Max: 4.76
Current: 1.41
0
4.76
Debt-to-EBITDA -0.81
CRIS's Debt-to-EBITDA is ranked lower than
99.99% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. CRIS: -0.81 )
Ranked among companies with meaningful Debt-to-EBITDA only.
CRIS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.76  Med: -1.15 Max: -0.06
Current: -0.81
-3.76
-0.06
Piotroski F-Score: 4
Altman Z-Score: -15.37
Beneish M-Score: -2.79
WACC vs ROIC
16.82%
-1256.79%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -593.42
CRIS's Operating Margin % is ranked lower than
74% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. CRIS: -593.42 )
Ranked among companies with meaningful Operating Margin % only.
CRIS' s Operating Margin % Range Over the Past 10 Years
Min: -771.08  Med: -113.33 Max: -35.24
Current: -593.42
-771.08
-35.24
Net Margin % -629.28
CRIS's Net Margin % is ranked lower than
75% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. CRIS: -629.28 )
Ranked among companies with meaningful Net Margin % only.
CRIS' s Net Margin % Range Over the Past 10 Years
Min: -802.59  Med: -105.54 Max: -27.72
Current: -629.28
-802.59
-27.72
ROE % -220.69
CRIS's ROE % is ranked lower than
91% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. CRIS: -220.69 )
Ranked among companies with meaningful ROE % only.
CRIS' s ROE % Range Over the Past 10 Years
Min: -220.69  Med: -29.93 Max: -11.29
Current: -220.69
-220.69
-11.29
ROA % -82.33
CRIS's ROA % is ranked lower than
86% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. CRIS: -82.33 )
Ranked among companies with meaningful ROA % only.
CRIS' s ROA % Range Over the Past 10 Years
Min: -82.33  Med: -25.84 Max: -10.23
Current: -82.33
-82.33
-10.23
ROC (Joel Greenblatt) % -13018.15
CRIS's ROC (Joel Greenblatt) % is ranked lower than
89% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. CRIS: -13018.15 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CRIS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -16681.33  Med: -2262.58 Max: -240.25
Current: -13018.15
-16681.33
-240.25
3-Year Revenue Growth Rate -32.10
CRIS's 3-Year Revenue Growth Rate is ranked lower than
77% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. CRIS: -32.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CRIS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -39.7  Med: -0.3 Max: 76.3
Current: -32.1
-39.7
76.3
3-Year EBITDA Growth Rate 63.30
CRIS's 3-Year EBITDA Growth Rate is ranked higher than
90% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. CRIS: 63.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CRIS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -49.4  Med: -9.1 Max: 63.3
Current: 63.3
-49.4
63.3
3-Year EPS without NRI Growth Rate 44.20
CRIS's 3-Year EPS without NRI Growth Rate is ranked higher than
87% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. CRIS: 44.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CRIS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -74.5  Med: -11.9 Max: 44.2
Current: 44.2
-74.5
44.2
GuruFocus has detected 2 Warning Signs with Curis Inc CRIS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CRIS's 30-Y Financials

Financials (Next Earnings Date: 2018-03-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

CRIS Guru Trades in Q4 2016

Jim Simons 361,100 sh (+151.99%)
First Eagle Investment 24,008,672 sh (unchged)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
» More
Q1 2017

CRIS Guru Trades in Q1 2017

Steven Cohen 500,400 sh (New)
First Eagle Investment 24,008,672 sh (unchged)
Jim Simons 348,600 sh (-3.46%)
» More
Q2 2017

CRIS Guru Trades in Q2 2017

Steven Cohen 912,721 sh (+82.40%)
First Eagle Investment 24,008,672 sh (unchged)
Jim Simons 261,700 sh (-24.93%)
» More
Q3 2017

CRIS Guru Trades in Q3 2017

First Eagle Investment 26,508,672 sh (+10.41%)
Steven Cohen Sold Out
Jim Simons 53,500 sh (-79.56%)
» More
» Details

Insider Trades

Latest Guru Trades with CRIS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
First Eagle Investment 2017-09-30 Add 10.41%0.01%$1.49 - $2.16 $ 0.88-53%26,508,672
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:XKRX:053030, NAS:CASC, BOM:531349, NAS:VTL, NAS:FOMX, NAS:MTEM, XSWX:SANN, NAS:MRNS, MIL:MLM, NAS:PIRS, NAS:CMRX, OTCPK:RCAR, XKRX:005690, NAS:ATHX, NAS:VTVT, NAS:ALBO, NAS:ECYT, TSX:ZYME, NAS:SBBP, HKSE:01035 » details
Traded in other countries:CUS.Germany,
Headquarter Location:USA
Curis Inc is a biotechnology company engaged in developing and commercializing drug candidates for the treatment of human cancers.

Curis is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, breast cancers, and others.

Ratios

vs
industry
vs
history
PB Ratio 4.78
CRIS's PB Ratio is ranked lower than
93% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. CRIS: 4.78 )
Ranked among companies with meaningful PB Ratio only.
CRIS' s PB Ratio Range Over the Past 10 Years
Min: 1.15  Med: 4.63 Max: 33.59
Current: 4.78
1.15
33.59
PS Ratio 13.95
CRIS's PS Ratio is ranked lower than
66% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. CRIS: 13.95 )
Ranked among companies with meaningful PS Ratio only.
CRIS' s PS Ratio Range Over the Past 10 Years
Min: 2.64  Med: 15.4 Max: 382
Current: 13.95
2.64
382
EV-to-EBIT -2.23
CRIS's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. CRIS: -2.23 )
Ranked among companies with meaningful EV-to-EBIT only.
CRIS' s EV-to-EBIT Range Over the Past 10 Years
Min: -674  Med: -8.5 Max: -1
Current: -2.23
-674
-1
EV-to-EBITDA -2.26
CRIS's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. CRIS: -2.26 )
Ranked among companies with meaningful EV-to-EBITDA only.
CRIS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1088.8  Med: -9.3 Max: -1.1
Current: -2.26
-1088.8
-1.1
EV-to-Revenue 13.11
CRIS's EV-to-Revenue is ranked lower than
63% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. CRIS: 13.11 )
Ranked among companies with meaningful EV-to-Revenue only.
CRIS' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.9  Med: 13.3 Max: 341.1
Current: 13.11
0.9
341.1
Current Ratio 5.15
CRIS's Current Ratio is ranked lower than
54% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. CRIS: 5.15 )
Ranked among companies with meaningful Current Ratio only.
CRIS' s Current Ratio Range Over the Past 10 Years
Min: 2.89  Med: 6.9 Max: 25.89
Current: 5.15
2.89
25.89
Quick Ratio 5.15
CRIS's Quick Ratio is ranked lower than
51% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. CRIS: 5.15 )
Ranked among companies with meaningful Quick Ratio only.
CRIS' s Quick Ratio Range Over the Past 10 Years
Min: 2.89  Med: 6.9 Max: 25.89
Current: 5.15
2.89
25.89
Days Sales Outstanding 99.63
CRIS's Days Sales Outstanding is ranked lower than
70% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. CRIS: 99.63 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRIS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.04  Med: 20.73 Max: 119.24
Current: 99.63
1.04
119.24
Days Payable 5.00
CRIS's Days Payable is ranked lower than
86% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. CRIS: 5.00 )
Ranked among companies with meaningful Days Payable only.
CRIS' s Days Payable Range Over the Past 10 Years
Min: 5  Med: 3791.15 Max: 5381.69
Current: 5
5
5381.69

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -18.00
CRIS's 3-Year Average Share Buyback Ratio is ranked lower than
61% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. CRIS: -18.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CRIS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -43.8  Med: -8.9 Max: -3.7
Current: -18
-43.8
-3.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 8.00
CRIS's Price-to-Net-Cash is ranked lower than
99.99% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. CRIS: 8.00 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CRIS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.78  Med: 7.06 Max: 46.33
Current: 8
1.78
46.33
Price-to-Net-Current-Asset-Value 6.77
CRIS's Price-to-Net-Current-Asset-Value is ranked lower than
99.99% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. CRIS: 6.77 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CRIS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.78  Med: 6.5 Max: 30.89
Current: 6.77
1.78
30.89
Price-to-Tangible-Book 6.77
CRIS's Price-to-Tangible-Book is ranked lower than
100% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. CRIS: 6.77 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CRIS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.64  Med: 5.99 Max: 945
Current: 6.77
1.64
945
Price-to-Median-PS-Value 0.91
CRIS's Price-to-Median-PS-Value is ranked lower than
78% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CRIS: 0.91 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CRIS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.09  Med: 1.16 Max: 21.07
Current: 0.91
0.09
21.07
Earnings Yield (Greenblatt) % -44.99
CRIS's Earnings Yield (Greenblatt) % is ranked lower than
79% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. CRIS: -44.99 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CRIS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -99.6  Med: -11.8 Max: -0.1
Current: -44.99
-99.6
-0.1

More Statistics

Revenue (TTM) (Mil) $9.00
EPS (TTM) $ -0.39
Beta2.50
Short Percentage of Float2.52%
52-Week Range $0.88 - 3.53
Shares Outstanding (Mil)163.98

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 8 7 7
EPS ($) -0.47 -0.46 -0.43
EPS without NRI ($) -0.47 -0.46 -0.43
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}